Lutikizumab - AbbVie

Drug Profile

Lutikizumab - AbbVie

Alternative Names: ABT-981

Latest Information Update: 20 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Abbott Laboratories
  • Developer AbbVie
  • Class Bispecific antibodies; Immunoglobulins; Monoclonal antibodies
  • Mechanism of Action Immunosuppressants; Interleukin 1 alpha inhibitors; Interleukin 1 beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Osteoarthritis

Most Recent Events

  • 03 Nov 2017 Efficacy and adverse events data from a phase IIa trial in Osteoarthritis presented at the the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting (ACR/ARHP-2017)
  • 01 Dec 2016 AbbVie completes a phase IIa trial for Osteoarthritis (of the knee) in USA, Australia, Canada, Denmark, France, Italy, Mexico, Netherlands, Puerto Rico, Spain and United Kingdom (NCT02087904)
  • 15 Jul 2016 AbbVie completes a phase IIa trial for Osteoarthritis (of the hand) in USA, Belgium, Denmark, France, Netherlands and Switzerland (NCT02384538)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top